ReviewStem cells translational medicine2024
Advances in 3D Bioprinted Cardiac Tissue Using Stem Cell-Derived Cardiomyocytes.
Review in Stem cells translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Engineering heterogeneous tissues and organs via multi-material bioprinting: Advances, challenges, and opportunities.Acta biomaterialia · 2026Review
- Current trends, applications, and challenges in three-dimensional bioprinting for cardiovascular disease models and therapies.iScience · 2026Review
- Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling.Advanced healthcare materials · 2026Review
- Versatile hiPSC Models and Bioengineering Platforms for Investigation of Atrial Fibrosis and Fibrillation.Cells · 2026Review
- Integrating Bioprinting and Increased Throughput: Next-Generation Models for Cardiac Research.International journal of molecular sciences · 2025Review
- 3D Bioprinting Functional Engineered Heart Tissues.International journal of molecular sciences · 2025Review
- Engineered heart tissues formed with cardiac progenitors and differentiated cardiomyocytes exhibit similar physiologic properties at differentiation-matched timepoints.Biofabrication · 2025Article
- Organ-Specific Strategies in Bioprinting: Addressing Translational Challenges in the Heart, Liver, Kidney, and Pancreas.Journal of functional biomaterials · 2025Review
- Integrative approaches in cardiac tissue engineering: Bridging cellular complexity to create accurate physiological models.iScience · 2025Review
- Application of instant assembly of collagen to bioprint cardiac tissues.APL bioengineering · 2025Article
- Advances in human induced pluripotent stem cell (hiPSC)-based disease modelling in cardiogenetics.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2025Article
- Advanced passive 3D bioelectronics: powerful tool for the cardiac electrophysiology investigation.Microsystems & nanoengineering · 2025Review
- Revolutionizing cardiovascular research: Human organoids as a Beacon of hope for understanding and treating cardiovascular diseases.Materials today. Bio · 2025Review
- Engineering immune organoids to regenerate host immune system.Current opinion in genetics & development · 2024Review
- The cutting-edge progress in bioprinting for biomedicine: principles, applications, and future perspectives.MedComm · 2024Review
- Editorial: Methods in cardiovascular biologics and regenerative medicine.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ultimate goal of cardiac tissue engineering is to generate new muscle to repair or replace the damaged heart. This requires advances in stem cell technologies to differentiate billions of cardiomyocytes, together with advanced biofabrication approaches such as 3D bioprinting to achieve the requisite structure and contractile function. In this concise review, we cover recent progress in 3D bioprinting of cardiac tissue using pluripotent stem cell-derived cardiomyocytes, key design criteria for engineering aligned cardiac tissues, and ongoing challenges in the field that must be addressed to realize this goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.